CAR-macrophages and innate immune reprogramming: mechanistic insights and translational horizons in cancer and inflammation

Archives of Orthopaedic and Trauma Surgery · Springer Nature · 2026-11-05 · DOI: 10.1007/s43538-026-00981-x

Аннотация

Macrophages are highly plastic innate immune effectors that integrate tissue-derived, metabolic, inflammatory, and developmental signals to regulate tumour progression and immune surveillance. This plasticity, however, can be exploited by the tumour microenvironment (TME), limiting macrophage-mediated phagocytosis, antigen presentation, and inflammatory activity. Chimeric antigen receptor-modified macrophages (CAR-M) have emerged as an engineered myeloid immunotherapy designed to couple antigen-specific recognition with phagocytosis, antigen presentation, and TME remodelling. This review examines the mechanistic basis of CAR-M function, with particular emphasis on macrophage state plasticity, CAR architecture, phagocytic regulation, immunosuppressive TME constraints, innate immune checkpoints, metabolic adaptation, and interactions with adaptive immunity. Preclinical studies demonstrate the capacity of CAR-M to enhance tumour recognition and reshape immunosuppressive niches, whereas early clinical investigation has primarily established feasibility, safety, tumour trafficking, and biological activity rather than definitive therapeutic efficacy. Key translational challenges include target selection, macrophage source and manufacturing, phenotypic stability after tumour entry, functional persistence, potency assessment, inflammatory toxicity, and scalable quality-controlled production. Emerging strategies incorporating synthetic signalling, metabolic or epigenetic reprogramming, and combinatorial checkpoint modulation may improve CAR-M function, but many remain preclinical or conceptual. By critically distinguishing established mechanisms from emerging and speculative approaches, this review positions CAR-M within the broader landscape of engineered innate immunity and outlines a translational roadmap for developing macrophage-based therapies in cancer. Graphical abstract Multidimensional immune reprogramming and translational trajectory of CAR-macrophage therapy- Chimeric antigen receptor engineered macrophages (CAR-Ms) integrate antigen-directed phagocytosis, antigen processing and presentation, and context-dependent inflammatory signalling to coordinate tumour clearance with adaptive immune activation. CAR-dependent immune-state, metabolic, and epigenetic reprogramming may further reshape the tumour microenvironment (TME), potentially enhancing immune infiltration and attenuating local immunosuppression. These mechanisms provide a framework for investigating CAR-M applications in oncology and emerging non-oncological settings. Clinical translation remains constrained by antigenheterogeneity, TME-mediated suppression, cellular persistence, manufacturing scalability, on-target/off-tumour effects, and inflammatory toxicity.

Читать у издателя →

Похожие статьи